Swiss National Bank Has $2.41 Million Stock Position in Schrödinger, Inc. (NASDAQ:SDGR)

Swiss National Bank increased its position in shares of Schrödinger, Inc. (NASDAQ:SDGR) by 1.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 125,100 shares of the company’s stock after buying an additional 1,500 shares during the period. Swiss National Bank owned 0.17% of Schrödinger worth $2,413,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Paradigm Asset Management Co. LLC acquired a new position in shares of Schrödinger during the 4th quarter worth about $50,000. Quarry LP grew its holdings in Schrödinger by 1,150.0% during the third quarter. Quarry LP now owns 2,825 shares of the company’s stock worth $52,000 after purchasing an additional 2,599 shares during the period. GAMMA Investing LLC increased its position in Schrödinger by 87.5% during the fourth quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock worth $54,000 after buying an additional 1,305 shares during the last quarter. KBC Group NV lifted its position in shares of Schrödinger by 73.9% in the fourth quarter. KBC Group NV now owns 4,361 shares of the company’s stock valued at $84,000 after buying an additional 1,853 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Schrödinger during the 3rd quarter worth approximately $102,000. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Piper Sandler reduced their price objective on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, February 27th. KeyCorp raised their price objective on shares of Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $32.29.

Schrödinger Price Performance

Shares of SDGR opened at $20.26 on Friday. The firm has a 50 day simple moving average of $23.09 and a two-hundred day simple moving average of $20.79. Schrödinger, Inc. has a one year low of $16.67 and a one year high of $29.15. The company has a market cap of $1.48 billion, a P/E ratio of -8.66 and a beta of 1.62.

Schrödinger (NASDAQ:SDGR) last issued its earnings results on Wednesday, February 26th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The business had revenue of $88.32 million for the quarter, compared to analyst estimates of $83.20 million. On average, analysts expect that Schrödinger, Inc. will post -2.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Geoffrey Craig Porges sold 5,491 shares of Schrödinger stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $21.76, for a total transaction of $119,484.16. Following the completion of the transaction, the chief financial officer now owns 27,544 shares of the company’s stock, valued at $599,357.44. This trade represents a 16.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.60% of the company’s stock.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.